Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy
Authors:
- Katherine SerranoKSKatherine Serrano
- Maria Gyongyossy-IssaMGMaria Gyongyossy-Issa
- Mladen KorbelikMKMladen Korbelik
- 1 July 2005
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 225 (2) , 215-223
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The complement system in B cell regulationMolecular Immunology, 2004
- The anaphylatoxins bridge innate and adaptive immune responses in allergic asthmaMolecular Immunology, 2004
- Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumorsPhotochemical & Photobiological Sciences, 2004
- Photodynamic therapy for cancerNature Reviews Cancer, 2003
- Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunctionThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Mouse Crry/p65 is a regulator of the alternative pathway of complement activationEuropean Journal of Immunology, 1993
- Solid Phase Enzyme Immunoassays for the Quantification of Serum Amyloid P (SAP) and Complement Component 3 (C3) Proteins in Acute-Phase Mouse SeraHormone and Metabolic Research, 1992
- HOW DOES PHOTODYNAMIC THERAPY WORK?Photochemistry and Photobiology, 1992
- Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1.Journal of Experimental Medicine, 1992
- Generation of Chemotactic Activity in Serum from Patients with Erythropoietic Protoporphyria and Porphyria Cutanea TardaNew England Journal of Medicine, 1981